Enjoy complimentary customisation on priority with our Enterprise License!
The polycystic kidney disease drugs market share is expected to increase by USD 510.69 million from 2021 to 2026, and the market’s growth momentum will accelerate at a CAGR of 6.7%. The growth of the polycystic kidney disease drugs market is being driven by the high prevalence of chronic kidney diseases. Worldwide, around 10% of the population is affected by chronic kidney disease, and lack of access to affordable treatment results in millions of deaths annually. Polycystic kidney disease, although rare, is a significant cause of chronic kidney disease and can lead to kidney failure. As the major form of chronic kidney disease, the prevalence of polycystic kidney disease contributes significantly to the strong prevalence of chronic kidney disease. The increasing prevalence of polycystic kidney disease is, therefore, a major factor driving the growth of the market.
This polycystic kidney disease drugs market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers polycystic kidney disease drugs market segmentation by type (ADPKD and ARPKD) and geography (North America, Europe, Asia, and Rest of World (ROW)).
To learn more about the Report Download the Free Report Sample
Vendors are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.The report analyzes the market’s competitive landscape and offers information on several market vendors, including:
This statistical study of the PKD drugs market encompasses successful business strategies deployed by the key vendors. The polycystic kidney disease drugs market is fragmented and the vendors are deploying organic and inorganic growth strategies to compete in the market.
To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
The polycystic kidney disease drugs market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.
The orphan product development is the notable driving the polycystic kidney disease drugs market growth, although factors such as lack of approved drugs may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the polycystic kidney disease drugs industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.
Key Polycystic Kidney Disease Drugs Market Driver
The US FDA's Office of Orphan Products Development is dedicated to advancing the development and evaluation of biologics, drugs, and devices for the treatment and diagnosis of rare diseases. It grants orphan status to biologics and drugs that are proven to be safe and effective in treating rare diseases and also funds clinical research through the Orphan Products Grants Program (OPGP) to assess the safety and efficacy of these treatments. In the EU, orphan drugs receive protocol assistance and ten-year market exclusivity. In the US, companies developing orphan drugs are eligible for incentives such as tax credits for clinical testing, exemption from prescription fees (unless indicated for additional non-orphan indications), and market exclusivity for seven years, during which the entry of generics is prohibited, thus protecting the market sales of orphan drugs.These special regulatory designations can help accelerate the approval and launch of new treatments, which is expected to drive market growth in the forecast period.
Key Polycystic Kidney Disease Drugs Market Trend
Increasing research funding is one of the key polycystic kidney disease (PKD) drugs market trends propelling the market growth. Fundamentally, polycystic kidney disease is a hereditary disease, which cannot be cured completely due to the lack of approved drugs. Despite the increasing prevalence of the disease, the market is witnessing a huge unmet need for therapeutics. This is leading various vendors and research institutes to research developing novel therapies. However, the market faces a challenge, as a major share of the vendors and research institutes that are conducting research are either small- or mid-sized companies, which lack funding to successfully conduct the research. As a result, these vendors and organizations rely on grants from organizations that provide research funding to complete their clinical trial research and launch the drug in the market. Meanwhile, there are a number of organizations that provide research funding, which is fueling the market growth.
Key Polycystic Kidney Disease Drugs Market Challenge
The lack of approved drugs is one of the key factors limiting the polycystic kidney disease drugs market growth. Unfortunately, the market has only one approved branded drug. Currently, the market is heavily dominated by the off-label use of various antibiotics, drugs treating hypertension, and NSAIDs to treat certain symptoms. Well, the symptomatic treatment of off-label drugs leads to limited patient adherence to the treatment with these drugs, as they provide only temporary relief from the symptoms and do not stop the progression of the disease. Moreover, the market faces a heavy threat from the increasing number of generic versions of various off-label drugs. Thus, the dominance of generics is expected to lead to value erosion in the market, and the lack of approved therapies is expected to continue to hinder the growth of the global polycystic kidney disease drugs market during the forecast period.
This polycystic kidney disease drugs market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.
For more insights on the market share of various regions Request for a FREE sample now!
37% of the market’s growth will originate from North America during the forecast period. The US and Canada are the key markets for the polycystic kidney disease drugs market in North America. Market growth in this region will be slower than the growth of the market in Asia.
Advances in the R&D of PKD will facilitate the polycystic kidney disease drugs market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.
COVID Impact and Recovery Analysis
In 2020, the outbreak of COVID-19 negatively impacted the market in focus in this region. However, in 2021, with the large-scale vaccination drives and the resumption of operations in the healthcare units, higher inflows of patients started resuming their polycystic kidney disease treatments in healthcare facilities in this region as compared with 2020. Thus, the increased requirements for novel drugs from the healthcare facilities will lead to the increased production of polycystic kidney disease drugs in the region, which will help the market in focus in North America to witness significant growth during the forecast period.
To gain further insights on the market contribution of various segments Request for a FREE sample
The polycystic kidney disease drugs market share growth by the ADPKD segment will be significant during the forecast period. Most people with ADPKD have defects in the polycystic kidney disease 1 gene, and about one out of six or seven people with ADPKD have a defective polycystic kidney disease 2 gene. Moreover, ADPKD is the most common form of polycystic kidney disease. The prevalence of ADPKD ranges from one in every 400 to 1,000 people globally. Thus, the increasing cases of ADPKD will propel the market growth during the forecast period.
This report provides an accurate prediction of the contribution of all the segments to the growth of the PKD drugs market size and actionable market insights on post COVID-19 impact on each segment.
Our report provides extensive information on the value chain analysis for the PKD drugs market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.
Kidney Transplantation Therapeutics market - The market share is expected to reach an estimated value of USD 1.16 billion by 2026 at an accelerating CAGR of 4.32%.
Kidney Stones market - The market share is expected to increase by USD 416.09 million from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 6.69%.
Polycystic Kidney Disease Drugs Market Scope |
|
Report Coverage |
Details |
Page number |
120 |
Base year |
2021 |
Forecast period |
2022-2026 |
Growth momentum & CAGR |
Accelerate at a CAGR of 6.7% |
Market growth 2022-2026 |
$ 510.69 million |
Market structure |
Fragmented |
YoY growth (%) |
5.11 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 37% |
Key consumer countries |
US, Canada, Germany, UK, and China |
Competitive landscape |
Leading companies, Competitive strategies, Consumer engagement scope |
Key companies profiled |
Apotex Inc., AstraZeneca Plc, Dr. Reddys Laboratories Ltd., Galapagos NV, Johnson and Johnson, Merck and Co. Inc., Novartis AG, Otsuka Holdings Co. Ltd., Palladio Biosciences Inc., Reata Pharmaceuticals Inc., Regulus Therapeutics Inc., Sanofi, Teva Pharmaceutical Industries Ltd., and XORTX Therapeutics Inc. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Five Forces Analysis
5 Market Segmentation by Type
6 Customer Landscape
7 Geographic Landscape
8 Drivers, Challenges, and Trends
9 Vendor Landscape
10 Vendor Analysis
11 Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.